CSIR-CDRI collaborates with Bengaluru based startup to develop novel therapeutics for cancer treatment

New Delhi: Sravathi AI Technology, a leading Indian startup in artificial intelligence (AI)-based drug discovery, and CSIR-CDRI (Central Drug Research Institute), Lucknow have announced a strategic collaboration to develop new therapeutics for the treatment of cancer.

Bangaluru based Sravathi AI Technology is focused on creating, discovering, and developing innovative advanced pharma and chemical products. Sravathi AI uses Hybrid Intelligence, combining the brilliance of the human mind and domain expertise with innovative AI technology to solve the most difficult problems.

The collaboration will entail the use of advanced artificial intelligence and computational tools developed at Sravathi to design novel chemical entities (NCEs) with anti-cancer properties.  CSIR-CDRI Lucknow will validate these predictions by synthesizing the NCEs and performing the required biological evaluation in vitro and in vivo. The two companies will work closely to optimize active compounds and select suitable candidates for clinical evaluation.

“We are very excited to collaborate with CSIR-CDRI, Lucknow to develop new therapeutics for cancer,” said Dr. Kishan Gurram, Founder and Managing Director of Sravathi. “By combining our artificial intelligence capabilities with CDRI’s capabilities in drug discovery, we believe that novel candidates that are effective and safe will be identified faster and at lower cost.”

“CDRI has deep expertise in cancer biology and has a demonstrated track record of drug discovery and development. It is a nodal laboratory for CSIR’s Pan-cancer Mission program which aims to deliver drugs to treat cancers with significant unmet need, such as triple negative breast cancer. This collaboration will help advance the goals of the Mission”, said Dr. Radha Rangarajan, Director CSIR-CDRI.